Profiling of phosphorylated ERBB2 and ERBB3 in end-stage tumors indicated that on-target activity of AF was sustained despite tumor progression, pointing to the emergence of alternative resistance mechanisms that could in the future be explored further. This evidence concerns the gene ERBB3 and neoplasm.